What is the likely diagnosis and recommended management for a 2‑year‑old male who had seizures beginning on the third day of life associated with documented hypoglycemia?

Likely Diagnosis: Hyperinsulinemic Hypoglycemia (Persistent or Perinatal Stress-Induced)

A 2-year-old with seizures beginning on day 3 of life associated with hypoglycemia most likely has hyperinsulinemic hypoglycemia (HI), either persistent genetic HI or perinatal stress-induced HI (PSHI). The timing (day 3) and association with seizures strongly suggest inappropriate insulin secretion as the underlying cause 1.

Diagnostic Approach

Critical Initial Evaluation

Obtain critical blood samples during the next hypoglycemic episode (glucose <50 mg/dL):

• Serum insulin level (should be inappropriately elevated, typically >2 μU/mL)
• Beta-hydroxybutyrate (should be suppressed, <1.5 mmol/L)
• Free fatty acids (should be suppressed)
• Cortisol and growth hormone (to exclude other causes)

The combination of detectable insulin with suppressed ketones during hypoglycemia confirms hyperinsulinism 1.

Distinguish Persistent vs. Perinatal Stress-Induced HI

Key differentiating factors:

• PSHI: Associated with prematurity, small for gestational age, birth asphyxia, maternal diabetes, or congenital heart disease. Typically resolves within weeks to months 1, 2.
• Persistent HI: Often genetic (KATP channel mutations most common), presents with severe hypoglycemia requiring high glucose infusion rates (>10-14 mg/kg/min), may be diazoxide-unresponsive 1, 3.

At 2 years old, if still symptomatic, this is almost certainly persistent genetic HI since PSHI would have resolved by now 1.

Genetic Testing

Obtain genetic testing for HI gene panel including ABCC8, KCNJ11, GLUD1, GCK, HADH, and others. This determines:

• Prognosis and treatment responsiveness
• Need for surgical intervention (focal vs. diffuse disease)
• Family counseling 1, 4

Management Strategy

Immediate Seizure Management

The seizures are secondary to hypoglycemia—treat the underlying hypoglycemia, not the seizures themselves. While the neonatal seizure guidelines 5 recommend phenobarbital as first-line for neonatal seizures, these are metabolic seizures that will resolve with glucose normalization 6, 7, 2.

• Maintain blood glucose >70 mg/dL at all times
• If actively seizing with documented hypoglycemia: immediate IV dextrose bolus (2 mL/kg of D10W), followed by continuous glucose infusion
• Do NOT start chronic antiseizure medications unless seizures persist despite normoglycemia 8, 2

Definitive Treatment: Diazoxide

Diazoxide is the first-line and only FDA-approved treatment for persistent hyperinsulinemic hypoglycemia 1.

Dosing protocol:

• Starting dose: 5-10 mg/kg/day divided into 2-3 doses (lower end for suspected PSHI or cardiac disease) 1
• Target dose range: 5-15 mg/kg/day (avoid exceeding 15 mg/kg/day due to increased adverse effects) 1
• Titrate by 2.5-5 mg/kg/day every 3-5 days based on glucose response (takes 5 days to reach steady state) 1
• Mandatory concurrent thiazide diuretic: chlorothiazide 10-20 mg/kg/day or hydrochlorothiazide 1-2 mg/kg/day to prevent fluid retention and pulmonary hypertension 1

Critical Monitoring for Adverse Effects

Before starting diazoxide:

• Thorough cardiac examination
• Baseline echocardiogram (especially if premature, small for gestational age, or any cardiac history) 1
• Baseline complete blood count (CBC)

During treatment:

• Monitor for pulmonary hypertension (increased risk in premature infants, those with cardiac disease, or respiratory distress)—repeat ECHO if respiratory symptoms develop 1
• CBC weekly for first month, then monthly (monitor for neutropenia, thrombocytopenia) 1
• Uric acid levels (risk of hyperuricemia) 1
• Watch for hypertrichosis (26-30% incidence, cosmetic only) 1
• Limit IV fluids to <150 mL/kg/day if on IV therapy 1

Response Assessment

Define diazoxide responsiveness:

• Maintains glucose >70 mg/dL during age-appropriate fast (12-18 hours for this age)
• OR develops ketonemia (>2 mmol/L) before glucose drops to ≤50 mg/dL 1

If diazoxide-unresponsive:

• Likely KATP channel mutation (recessive ABCC8/KCNJ11)
• Requires 18F-DOPA PET/CT to distinguish focal vs. diffuse disease
• Focal disease: curative surgical resection
• Diffuse disease: near-total pancreatectomy (95-98%) or medical alternatives (octreotide, continuous feeds) 1

Neurological Prognosis and Follow-Up

Critical caveat: Hypoglycemic brain injury is a major concern 3, 7, 2.

• Seizures from day 3 of life suggest significant early hypoglycemic exposure
• Parieto-occipital injury is characteristic of hyperinsulinemic hypoglycemia 3, 7
• Risk of developmental delay, learning disabilities, and epilepsy (even after hypoglycemia resolves) 3, 7, 2
• Watch for gaze preference or visual abnormalities—may herald occipital lobe epilepsy or infantile spasms 3

Recommended monitoring:

• Formal neurodevelopmental assessment at regular intervals
• Brain MRI if not already done (assess for white matter injury)
• EEG if any concerning neurological signs develop
• Early intervention services as needed 3, 2

Duration of Treatment

If diazoxide-responsive and this was PSHI (unlikely given age 2):

• Attempt weaning after 4-6 months with supervised fasting study 3

If persistent genetic HI:

• May require years of treatment
• Some forms (GDH-HI, HNF4A-HI) may improve with age
• KATP-HI often requires lifelong management or surgery 1

Key principle: The goal is preventing recurrent hypoglycemia to minimize further neurological injury, not just treating current symptoms 8, 2, 9.